China’s Sinopharm Begins Phase 3 COVID-19 Vaccine Trial in United Arab Emirates

China-owned pharmaceutical company Sinopharm has begun a phase 3 clinical trial of its COVID-19 vaccine candidate in the United Arab Emirates.

The study will evaluate two formulations of the vaccine in 15,000 volunteers ages 18-60 and is expected to last for three to six months.

Sinopharm’s inactivated COVID-19 vaccine demonstrated a 100 percent immune response in phase 1 and 2 clinical trials.